PMGC Holdings Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- PMGC Holdings Inc. operates as a diversified holding company focused on acquiring, managing, and growing cash-flowing businesses primarily in the manufacturing, biopharmaceutical, research, and investment sectors. The company, through its wholly owned subsidiaries, offers biopharmaceutical development including the lead asset EL-22, a first-in-class engineered probiotic therapy designed to preserve muscle mass during weight loss treatments such as GLP-1 receptor agonists; medical scientific research and development activities via PMGC Research Inc.; multi-strategy investment, lending, and portfolio management through PMGC Capital LLC; custom IT packaging solutions for electronics, data centers, and technology manufacturers via Pacific Sun Packaging Inc.; and precision CNC machining, aerospace, and defense manufacturing services through AGA Precision Systems LLC. PMGC Holdings maintains operations in the United States, targeting commercial, industrial, and healthcare customers with scalable, compliant products and services. Incorporated in 2020 and headquartered in Newport Beach, California, the company was formerly known as Elevai Labs Inc. and underwent a strategic reorganization and name change in December 2024. Recent developments include the sale of its Elevai Skincare subsidiary to Carmell Corporation in January 2025 for immediate financial benefit and future royalties; completion of the acquisition of Pacific Sun Packaging Inc. in July 2025 for $1.148 million plus earnout to enhance exposure to semiconductor and AI infrastructure; acquisition of AGA Precision Systems LLC in July 2025 and subsequent purchase of Indarg Engineering Inc. in Q4 2025 to expand aerospace and defense capabilities; partnerships such as with Yuva Biosciences for AI-powered therapies and Modulant Biosciences for animal model studies on EL-22; positive FDA feedback supporting an IND submission for Phase 2 trials of EL-22; new US patent filings for EL-22 and EL-32 programs; multiple financing activities including $8.0 million public offering in 2024, $1.9 million and $1.67 million warrant inducements in 2025, and a $1.48 million registered direct offering; and reverse stock splits in March and August 2025 to maintain Nasdaq listing compliance.
Company News
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
PMGC Holdings Inc. Announces Anticipated Reverse Stock Split
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially
PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement
PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.
PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.
NorthStrive Defense Tech Engages Defense Software and Security Firm Deploy360 to Validate Patented GPS-Denied Drone Navigation Technology Under Option to License
NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications
NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications
NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression
PMGC Holdings Inc. Announces Merger of AGA Precision Systems into A&B Aerospace
Wall Street is Watching These Biotechs
NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences